113 patients with advanced melanoma who received treatment with anti-PD1 (47 pembrolizumab 1 nivolumab), anti-CTLA4 (23 ipilimumab) or anti-CTLA4 plus Anti-PD1 (42 ipilimumab plus nivolumab). The gene discussed is CTLA4; the disease is melanoma.